This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Veterans Advancing ALS/MND Wins Sanofi US Innovation Challenge: Collaborate Innovate

Stocks in this article: SAN SNY

BRIDGEWATER, N.J., May 12, 2014 /PRNewswire/ -- Sanofi US announced the winner of its second Innovation Challenge: Collaborate Innovate. The winner, Veterans Advancing ALS/MND , is a partnership that comprises Innovative Solutions Consortium and Johns Hopkins University.  In the spirit of collaboration, Sanofi's Partners in Patient Health and North America Research & Development Hub coordinated the Collaborate Innovate Challenge to strengthen the patient voice in the drug development process. Independent judges selected the winning team from four finalists selected to present their concepts to a live audience at an event at the Sanofi US Bridgewater campus.

Veterans Advancing ALS/MND Team Wins Sanofi's Partners in Patient Health and North America Research & Development Hub Collaborate Innovate Challenge

Veterans Advancing ALS/MND will conduct data analysis to provide new clues to the higher incidence of ALS in veterans. ALS (Amyotrophic Lateral Sclerosis/Motor Neuron Disease, aka ALS, or " Lou Gehrig's Disease") is a neurodegenerative disease with no substantial therapies. The concept will connect open innovation, reliable veterans' organizations and the ALS research community to provide new conclusive insights about ALS and accelerate application of individualized therapies.

"Winning this challenge provides Veterans Advancing ALS/MND with urgently needed resources to help ALS/MND veterans receive better care, as well as develop new therapies tailored to individual patient needs," said Steve Hunt, Executive Director, Innovative Solutions Consortium. "Our approach will demonstrate advances in individualized treatments for many diseases, not just ALS/MND."

For the past two months, each of the four finalist teams received mentorship from Sanofi team members and functional experts in business strategy, marketing and communications, systems thinking, decision sciences, and healthcare venture capital, drawing on cooperative insights to refine their solution before presenting to the judges.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs